Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase III SatraGO-1 and SatraGO-2 Randomized Trials
Authors:
- César A. BriceñoCBCésar A. Briceño
- Oluwatobi O. IdowuOIOluwatobi O. Idowu
- Jwu Jin KhongJKJwu Jin Khong
- Thomas KuenzelTKThomas Kuenzel
- Ann Q. TranATAnn Q. Tran
- Christopher BrittainCBChristopher Brittain
- Atsushi AzumiAAAtsushi Azumi
- Laura BrockwellLBLaura Brockwell
- Nima GhadiriNGNima Ghadiri
- Mariano CoronelMCMariano Coronel
- Thorsten RufTRThorsten Ruf
- Dongmei LiDLDongmei Li
Open Access
- 7 September 2026
- journal article
- Published by Elsevier in Ophthalmology
Abstract
No abstract availableFunding Information
- Roche
This publication has 37 references indexed in Scilit:
- THRIVEOphthalmology, 2026
- The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye diseaseReviews in Endocrine and Metabolic Disorders, 2026
- IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese PatientsJAMA Ophthalmology, 2025
- Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 TrialsOphthalmology and Therapy, 2025
- Reactivation After Teprotumumab Treatment for Active Thyroid Eye DiseaseAmerican Journal of Ophthalmology, 2023
- Frequency and Patterns of Hearing Dysfunction in Patients Treated with TeprotumumabOphthalmology, 2023
- Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStarMultiple Sclerosis and Related Disorders, 2022
- Pathophysiology of thyroid-associated orbitopathyBest Practice & Research Clinical Endocrinology & Metabolism, 2022
- Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experienceDrug Discovery Today, 2021
- Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical TrialAmerican Journal of Ophthalmology, 2018